Patrick O'Brien, General Counsel at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 50,000 shares at $70.78 ($3.6M) on 2021-01-06, disclosed to the SEC on 2021-01-07.
Seasonal sale ($3.6M) by General Counsel — this insider has traded ARWR in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $70.78 | 1,142 | $81K | 2.2% |
| 2 | $70.78 | 1,142 | $81K | 2.2% |
| 3 | $72.27 | 10,615 | $767K | 21.2% |
| 4 | $72.27 | 10,615 | $767K | 21.2% |
| 5 | $72.67 | 13,243 | $962K | 26.6% |
| 6 | $72.67 | 13,243 |
| $962K |
| 26.6% |
| Total | $72.41 avg | 50,000 | $3.6M | 100% |
| Filing → |
| GLRE | SELL | 2025-05-14 | $267K | — | Filing → |
| ARWR | SELL | 2025-01-07 | $1.3M | — | Filing → |
| ARWR | SELL | 2024-01-05 | $1.9M | — | Filing → |